Barz S, Hummel T, Pauli E, Majer M, Lang C J, Kobal G
Department of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Germany.
Neurology. 1997 Nov;49(5):1424-31. doi: 10.1212/wnl.49.5.1424.
Decrease of olfactory function in patients with Parkinson's disease (PD) has been reported by several authors. The current study investigated olfaction in PD patients using olfactory event-related potentials (OERPs) as an electrophysiologic correlate of olfactory function in combination with psychophysical testing. A specific focus was the influence of antiparkinsonian drugs. We investigated PD patients treated with antiparkinsonian drugs (n = 13) and PD patients who received no pharmacologic treatment (n = 18). They were compared to age- and sex-matched control subjects (n = 38). To obtain OERPs, stimulants were chosen to stimulate specifically the olfactory nerve (2.1 ppm vanillin, 0.8 ppm H2S). In addition, chemosomatosensory event-related potentials were recorded after trigeminal stimulation with 52% v/v CO2. Moreover, the subjects' ability to identify and to discriminate odorants was tested by means of a "squeeze bottle" technique. The study yielded the following major results: (1) Odor identification was impaired in PD patients. It was not influenced by treatment with antiparkinsonian drugs. (2) The OERP latencies were prolonged in both PD patients taking and not taking antiparkinsonian drugs; however, this effect was more pronounced in PD patients taking antiparkinsonian drugs. (3) The intranasal chemosensory trigeminal system seemingly was neither affected by the neuronal degeneration seen in PD nor by treatment with antiparkinsonian drugs.
多位作者报道过帕金森病(PD)患者嗅觉功能减退。本研究使用嗅觉事件相关电位(OERPs)作为嗅觉功能的电生理指标,并结合心理物理学测试,对PD患者的嗅觉进行了调查。特别关注的是抗帕金森病药物的影响。我们调查了接受抗帕金森病药物治疗的PD患者(n = 13)和未接受药物治疗的PD患者(n = 18)。将他们与年龄和性别匹配的对照受试者(n = 38)进行比较。为了获得OERPs,选择刺激物专门刺激嗅神经(2.1 ppm香兰素,0.8 ppm硫化氢)。此外,在用52% v/v二氧化碳进行三叉神经刺激后,记录化学躯体感觉事件相关电位。此外,通过“挤压瓶”技术测试受试者识别和区分气味的能力。该研究得出以下主要结果:(1)PD患者的气味识别能力受损。它不受抗帕金森病药物治疗的影响。(2)服用和未服用抗帕金森病药物的PD患者的OERP潜伏期均延长;然而,这种影响在服用抗帕金森病药物的PD患者中更为明显。(3)鼻内化学感觉三叉神经系统似乎既不受PD中所见神经元变性的影响,也不受抗帕金森病药物治疗的影响。